OncoMatch/Clinical Trials/NCT02479698
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
Is NCT02479698 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Allogeneic BK-specific Cytotoxic T-lymphocytes for acquired immunodeficiency syndrome.
Treatment: Allogeneic BK-specific Cytotoxic T-lymphocytes — This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and/or JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and/or JC virus.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Tumor Agnostic
Demographics
Prior therapy
Must have received: antiviral therapy (cidofovir, leflunomide) — current
Patients who are currently receiving treatment with cidofovir, leflunomide, or other antiviral therapy with no response, will be eligible for CTL infusion
Cannot have received: prednisone (prednisone)
Patients receiving prednisone > 0.5 mg/kg/day at time of enrollment
Cannot have received: ATG (ATG)
have received ATG within 14 days
Cannot have received: donor lymphocyte infusion (donor lymphocyte infusion (DLI))
have received donor lymphocyte infusion (DLI) ... within 28 days
Cannot have received: Campath (Campath)
have received ... Campath within 28 days of enrollment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT02479698 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior prednisone, ATG, donor lymphocyte infusion disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify